RQ Bio Secures $115 Million in Latest Pre-Seed Funding Round

RQ Bio secured $115 million in its latest Pre-Seed, adding another data point to the Legal, Regulatory & Compliance funding market.

RQ Bio Raises $115 million in Funding

RQ Bio Raises $115 Million Series A To Advance Influenza Prevention Antibody Program. RQ Bio is a private biotechnology company developing long-acting antibody therapeutics for the prevention of influenza in high-risk and immunocompromised populations.

Investors Behind the Funding

The round was backed by Frazier Life Sciences. Capvizr tracks this investor activity alongside sector momentum, co-investor patterns, and recent comparable raises.

Company Profile and Market Context

RQ Bio operates in Legal, Regulatory & Compliance. RQ Bio's financing adds to recent private-market activity.

Strategic Use of Funds

Advance Influenza Prevention Antibody Program.

Looking Ahead

RQ Bio Raises $115 Million Series A To Advance Influenza Prevention Antibody Program

Source reference: original announcement/article.